[HTML][HTML] Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines
M Holmberg, HCD Aass, O Dalgard, E Samuelsen… - Scientific Reports, 2023 - nature.com
Patients with HBeAg-negative chronic hepatitis B may experience an immune response after
stopping nucleos (t) ide analogue (NA) therapy, which may potentially trigger HBsAg loss or …
stopping nucleos (t) ide analogue (NA) therapy, which may potentially trigger HBsAg loss or …
Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines.
M Holmberg, HCD Aass, O Dalgard… - Scientific …, 2023 - search.ebscohost.com
Patients with HBeAg-negative chronic hepatitis B may experience an immune response after
stopping nucleos (t) ide analogue (NA) therapy, which may potentially trigger HBsAg loss or …
stopping nucleos (t) ide analogue (NA) therapy, which may potentially trigger HBsAg loss or …
Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines.
M Holmberg, HCD Aass, O Dalgard, E Samuelsen… - Scientific …, 2023 - europepmc.org
Patients with HBeAg-negative chronic hepatitis B may experience an immune response after
stopping nucleos (t) ide analogue (NA) therapy, which may potentially trigger HBsAg loss or …
stopping nucleos (t) ide analogue (NA) therapy, which may potentially trigger HBsAg loss or …
[HTML][HTML] Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines
M Holmberg, HCD Aass, O Dalgard… - Scientific …, 2023 - ncbi.nlm.nih.gov
Patients with HBeAg-negative chronic hepatitis B may experience an immune response after
stopping nucleos (t) ide analogue (NA) therapy, which may potentially trigger HBsAg loss or …
stopping nucleos (t) ide analogue (NA) therapy, which may potentially trigger HBsAg loss or …
Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines
M Holmberg, HCD Aass, O Dalgard… - Scientific …, 2023 - pubmed.ncbi.nlm.nih.gov
Patients with HBeAg-negative chronic hepatitis B may experience an immune response after
stopping nucleos (t) ide analogue (NA) therapy, which may potentially trigger HBsAg loss or …
stopping nucleos (t) ide analogue (NA) therapy, which may potentially trigger HBsAg loss or …
Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines
M Holmberg, HCD Aass, O Dalgard… - Scientific …, 2023 - ui.adsabs.harvard.edu
Patients with HBeAg-negative chronic hepatitis B may experience an immune response after
stopping nucleos (t) ide analogue (NA) therapy, which may potentially trigger HBsAg loss or …
stopping nucleos (t) ide analogue (NA) therapy, which may potentially trigger HBsAg loss or …
Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines
M Holmberg, HC Aass, O Dalgard, E Samuelsen… - Scientific Reports, 2023 - duo.uio.no
Patients with HBeAg-negative chronic hepatitis B may experience an immune response after
stopping nucleos (t) ide analogue (NA) therapy, which may potentially trigger HBsAg loss or …
stopping nucleos (t) ide analogue (NA) therapy, which may potentially trigger HBsAg loss or …
Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines.
M Holmberg, HCD Aass, O Dalgard, E Samuelsen… - Scientific …, 2023 - europepmc.org
Patients with HBeAg-negative chronic hepatitis B may experience an immune response after
stopping nucleos (t) ide analogue (NA) therapy, which may potentially trigger HBsAg loss or …
stopping nucleos (t) ide analogue (NA) therapy, which may potentially trigger HBsAg loss or …